{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=9", "query": { "intervention": "Investigator's Treatment of Choice", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 245, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T22:35:27.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07155187", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "c-MET" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2025-12-10", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 16, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 13 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155187" }, { "nct_id": "NCT04111107", "title": "Precision Medicine for Patients With Identified Actionable Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Lymphoma", "Multiple Myeloma", "Malignant Neoplasm", "Mutation Abnormality" ], "interventions": [ { "name": "Investigational Agent", "type": "DRUG" }, { "name": "Supportive Care Regimens", "type": "OTHER" }, { "name": "Next Gen Sequencing Report", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-04-22", "completion_date": "2023-02-09", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111107" }, { "nct_id": "NCT04380636", "title": "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo for olaparib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2020-07-06", "completion_date": "2029-07-06", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 33, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380636" }, { "nct_id": "NCT02625623", "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "Gastric Cancer Third Line" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2015-12-28", "completion_date": "2019-11-13", "has_results": true, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 28, "location_summary": "Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625623" }, { "nct_id": "NCT05198934", "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 160, "start_date": "2022-04-19", "completion_date": "2026-04-14", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05198934" }, { "nct_id": "NCT00562965", "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "inotuzumab ozogamicin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone/prednisolone", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-11", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 17, "location_summary": "Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more", "locations": [ { "city": "Mission Hills", "state": "California" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Novi", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562965" }, { "nct_id": "NCT00117598", "title": "Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Temsirolimus (CCI-779)", "type": "DRUG" }, { "name": "Investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2005-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-03-30", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Milford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117598" }, { "nct_id": "NCT03366493", "title": "The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Intraepithelial Neoplasia Grade 2/3" ], "interventions": [ { "name": "FRD", "type": "COMBINATION_PRODUCT" }, { "name": "Cytology", "type": "OTHER" }, { "name": "HPV testing", "type": "OTHER" }, { "name": "Colposcopy", "type": "PROCEDURE" }, { "name": "ECC", "type": "PROCEDURE" }, { "name": "Biospy", "type": "PROCEDURE" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER", "PROCEDURE" ], "sponsor": "GY Highland Biotech LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "20 Years to 60 Years · Female only" }, "enrollment_count": 200, "start_date": "2017-12-07", "completion_date": "2018-12-07", "has_results": false, "last_update_posted_date": "2017-12-08", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03366493" }, { "nct_id": "NCT03493854", "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab IV", "type": "DRUG" }, { "name": "FDC of Pertuzumab and Trastuzumab SC", "type": "DRUG" }, { "name": "Trastuzumab IV", "type": "DRUG" }, { "name": "Trastuzumab SC", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Post-operative Radiotherapy", "type": "RADIATION" }, { "name": "Hormone Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2018-06-14", "completion_date": "2023-06-02", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 4, "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Rockville", "state": "Maryland" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Lakewood", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493854" }, { "nct_id": "NCT03066778", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer (SCLC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Normal saline solution", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2017-05-02", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-10-13T22:35:27.397Z", "location_count": 27, "location_summary": "Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Munster", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066778" } ] }